Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Dusseldorf - Delayed Quote EUR

Akeso Inc (4RY.DU)

Compare

8.70

-0.05

(-0.57%)

As of 12:30:21 PM GMT+1. Market Open.

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate), is Akeso's first ADC drug to enter clinical studies.

PR Newswire 4 days ago

AKESF
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the pharmaceutical sector.

CNN Business 5 days ago

AKESF
Q4 2024 Summit Therapeutics Inc Earnings Call

Q4 2024 Summit Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 6 days ago

SMMT

PFE

AKESF
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

PR Newswire 6 days ago

AKESF
Exploring 3 High Growth Tech Stocks with Potential Expansion

As global markets continue to navigate a landscape marked by rising inflation and fluctuating interest rates, U.S. stock indexes are climbing toward record highs, with growth stocks outpacing value shares despite small-cap stocks lagging behind their larger counterparts. In this environment, identifying high-growth tech stocks that demonstrate robust potential for expansion can be particularly appealing to investors seeking opportunities in sectors poised for innovation and transformation.

Simply Wall St. 10 days ago

AKESF
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by the company.

PR Newswire 10 days ago

AKESF
3 Prominent Stocks Estimated To Be Undervalued In February 2025

As global markets navigate a landscape of rising inflation and cautious monetary policies, U.S. stock indexes are climbing toward record highs, buoyed by optimism surrounding trade negotiations and robust earnings reports. In this environment, identifying undervalued stocks can be crucial for investors seeking opportunities that may offer potential growth despite broader market uncertainties.

Simply Wall St. 12 days ago

AKESF

ASMVF

ASMVY
Top Growth Companies With Insider Ownership In February 2025

As global markets continue to navigate a landscape marked by accelerating U.S. inflation and climbing stock indexes, growth stocks have notably outperformed their value counterparts, capturing investor interest. In this environment, companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business operations.

Simply Wall St. 12 days ago

AKESF
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases.

PR Newswire 17 days ago

AKESF
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC

Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody, cadonilimab. This study is evaluating the efficacy of cadonilimab compared to sugemalimab (PD-L1) as a consolidation therapy for patients with locally advanced, non-resectable, non-small cell lung cancer (NSCLC) who have not ex

PR Newswire 18 days ago

AKESF
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific antibody. This clinical study, conducted in China, compares ivonescimab in combination with platinum-based chemotherapy to tislelizumab (a PD-1 inhibitor) combined with platinum-based chemotherapy as a first-line treatment for squamous non-small cell lung c

PR Newswire 25 days ago

AKESF
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis. The strategic combination of drugs such as gumokimab and ebronucimab (PCSK9) to address the differentiated treatment needs of psoriasis has

PR Newswire last month

AKESF
High Growth Tech Stocks To Watch In January 2025

As global markets witness a rebound driven by easing core inflation in the U.S. and strong bank earnings, major indices such as the S&P 500 and Nasdaq Composite have recorded significant gains, reflecting an optimistic sentiment despite recent economic challenges. In this environment, identifying high growth tech stocks involves focusing on companies that demonstrate resilience through innovation and adaptability to changing market dynamics.

Simply Wall St. last month

AKESF
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxaliplatin and capecitabine for the first-line treatment of unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in a Phase III clinical study (COMPASSION-15/AK104-302). The results of the COMPASS

PR Newswire last month

AKESF
Akeso Received Payment for the Development Collaboration on Tagitanlimab

On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclonal antibody targeting PD-L1, following its recent marketing approval by China's National Medical Products Administration.

PR Newswire last month

AKESF
Insider-Favored Growth Stocks To Watch In January 2025

As global markets navigate choppy waters marked by inflation concerns and political uncertainties, investors are closely watching economic indicators and policy shifts that could influence future growth trajectories. In this environment, stocks with high insider ownership can offer a unique perspective on potential growth opportunities, as insiders often have a deep understanding of their company's long-term prospects.

Simply Wall St. last month

AKESF

RUSTA.ST
Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place on January 13, 2025, in San Francisco, California. The company's founder, chairwoman, president, and CEO, Dr. Michelle Xia will share the latest developments and plans for its globally leading programs, including ivonescimab (PD-1/VEGF bispecific antibody), cadonilimab (PD-1/CTLA-4 bispecific antibody), and ligufalimab (CD47 monoclo

PR Newswire last month

AKESF
Exploring High Growth Tech Stocks with Promising Potential

In the current market environment, characterized by cautious sentiment following the Federal Reserve's recent rate cut and ongoing political uncertainties, smaller-cap indexes have experienced notable challenges. Despite these hurdles, strong economic data such as increased consumer spending and positive jobs reports suggest potential opportunities for high-growth tech stocks. In this context, identifying promising tech stocks involves assessing their ability to capitalize on technological...

Simply Wall St. 2 months ago

AKESF
Top Growth Companies With Strong Insider Ownership December 2024

As global markets navigate a landscape marked by rate cuts from the ECB and SNB, alongside expectations for a Federal Reserve cut, growth stocks have continued to outperform their value counterparts, with the Nasdaq Composite reaching new heights. Amidst this backdrop of economic shifts and market volatility, companies with strong insider ownership can offer unique insights into potential growth trajectories, as insiders often align their interests closely with shareholders.

Simply Wall St. 2 months ago

AKESF

MDCLF
Ottimo raises $140M to compete in chase for new type of cancer drug

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and VEGF-blocking cancer treatments.

BioPharma Dive 2 months ago

AKESF

Performance Overview

Return	4RY.DU	HANG SENG INDEX
YTD	+20.83%	+14.69%
1-Year	+64.15%	+38.68%
3-Year	+271.79%	+2.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akeso Inc (4RY.DU)

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine

Q4 2024 Summit Therapeutics Inc Earnings Call

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Exploring 3 High Growth Tech Stocks with Potential Expansion

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

3 Prominent Stocks Estimated To Be Undervalued In February 2025

Top Growth Companies With Insider Ownership In February 2025

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC

Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC

Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

High Growth Tech Stocks To Watch In January 2025

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

Akeso Received Payment for the Development Collaboration on Tagitanlimab

Insider-Favored Growth Stocks To Watch In January 2025

Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks with Promising Potential

Top Growth Companies With Strong Insider Ownership December 2024

Ottimo raises $140M to compete in chase for new type of cancer drug

Performance Overview